GRIN2D Antibody

What is GRIN2D and why is it relevant to neurological research?

GRIN2D encodes the GluN2D subunit protein of N-methyl-D-aspartate (NMDA) receptors, which are ligand-gated ionotropic channels mediating excitatory synaptic transmission in the central nervous system. These receptors are critical for calcium-permeable components of synaptic transmission. Variants in GRIN2D have been associated with a spectrum of neurodevelopmental disorders, particularly developmental and epileptic encephalopathies, making it a significant target for neurological research . The functional analysis of GRIN2D variants has revealed that mutations can affect receptor surface expression, agonist potency, and channel open probability, directly impacting neuronal signaling.

What are the known functional domains of GRIN2D important for antibody targeting?

The GluN2D protein contains several functionally important domains that serve as potential epitopes for antibody generation:

• N-terminal domain (amino acids 28-584): Contains ligand-binding regions

• Pre-M1 helix: Associated with channel gating

• Transmembrane domain M3: Critical for ion permeability

• Intracellular carboxyl terminal domain: Involved in receptor trafficking and signaling

Key variant locations that have been identified in research include positions Ser573, Leu670, Ala675, Ala678, Ser1271, and Arg1313, which affect receptor function when mutated .

How does GRIN2D expression differ across tissues and developmental stages?

GRIN2D has traditionally been considered primarily neuronal, but recent research has expanded its known expression profile. Notably, GRIN2D has been identified as a novel endothelial target in colorectal cancer , suggesting expression beyond neural tissues. In neurological contexts, expression patterns vary during development and across brain regions. Understanding this differential expression is crucial when selecting control tissues for antibody validation and interpreting experimental results.

What controls should be included when validating GRIN2D antibody specificity?

A robust validation protocol for GRIN2D antibodies should include:

The discrepancy between calculated (143.8 kDa) and observed (72 kDa) molecular weights should be investigated as it may reflect processing or degradation of the target protein .

What are the optimal fixation and antigen retrieval methods for GRIN2D immunohistochemistry?

For successful immunohistochemical detection of GRIN2D:

• Fixation: 4% paraformaldehyde provides better epitope preservation than formalin for membrane proteins like GRIN2D

• Antigen retrieval: Heat-induced epitope retrieval (HIER) using citrate buffer (pH 6.0) for 20 minutes is generally effective

• Blocking: 5-10% normal serum from the same species as the secondary antibody for 1 hour at room temperature

• Antibody dilution: Optimal dilutions vary by supplier (typical range 1:15-1:50 for IHC as indicated in product data)

• Incubation: Overnight at 4°C for primary antibody improves specific binding

Researchers should validate these conditions for each specific antibody and tissue type, as GRIN2D detection in neuronal versus non-neuronal tissues may require protocol optimization.

How can functional validation complement immunological detection of GRIN2D?

Beyond antibody-based detection, functional validation strategies include:

• Electrophysiology: Patch-clamp recordings to measure NMDA receptor function in cells expressing wild-type versus variant GRIN2D

• Calcium imaging: Quantification of calcium influx in response to receptor activation

• Surface trafficking assays: Assessment of receptor expression at the cell membrane

• Cell viability studies: Examination of potential neurotoxicity associated with GRIN2D variants

These functional approaches provide crucial complementary data to antibody-based protein detection methods, enabling correlation between protein expression and physiological function.

How should researchers approach epitope selection when designing custom GRIN2D antibodies?

Strategic epitope selection is critical for successful GRIN2D antibody development:

• Extracellular domains (amino acids 28-584): Ideal for detecting surface-expressed GRIN2D in non-permeabilized cells

• Intracellular C-terminal region: Useful for total GRIN2D detection regardless of trafficking status

• Variant-specific epitopes: For mutation-specific antibodies targeting known pathogenic variants

Commercial antibodies target various regions, including amino acids:

• 330-480: Internal region

• 644-693: Transmembrane region

• 671-720: Contains key variant sites associated with pathology

Researchers should consider the specific biological question when selecting or designing antibodies. For instance, studies of receptor trafficking would benefit from antibodies targeting extracellular epitopes for surface labeling.

What strategies can overcome cross-reactivity with other NMDA receptor subunits?

NMDA receptor subunits share structural homology, creating challenges for antibody specificity. To minimize cross-reactivity:

• Target unique sequences with <40% homology to other GRIN family members

• Validate antibodies against cells expressing specific GRIN subunits (GRIN2A, GRIN2B, GRIN2C)

• Include epitope alignment analysis against all GRIN subtypes during antibody design

• Perform immunoprecipitation followed by mass spectrometry to confirm binding specificity

• Use knockout/knockdown validation approaches in multiple cell systems

The pre-M1 helix and C-terminal domains show greater sequence divergence between GRIN subtypes compared to transmembrane regions and may offer better specificity.

What are the optimal detection methods for low-abundance GRIN2D in non-neuronal tissues?

When studying GRIN2D in contexts with lower expression levels, such as tumor endothelial cells :

RTqPCR validation should accompany protein detection methods to correlate transcript and protein levels, particularly in tissues with variable expression .

How should researchers interpret differences between calculated and observed molecular weights of GRIN2D?

The calculated molecular weight of GRIN2D is 143.8 kDa, yet observed weights in Western blots often vary:

• 72 kDa: Reported by some commercial antibodies

• 143.8 kDa: Theoretical full-length protein

This discrepancy may reflect:

• Post-translational modifications (glycosylation, phosphorylation)

• Proteolytic processing of the receptor

• Alternative splicing variants

• Technical factors (SDS-PAGE conditions, reducing agents)

Researchers should employ multiple antibodies targeting different epitopes to confirm identity of detected bands and consider protease inhibitor cocktails during sample preparation to prevent degradation artifacts.

What approaches can resolve contradictory GRIN2D antibody staining patterns in patient samples?

When confronted with inconsistent staining patterns:

• Compare multiple antibodies targeting different epitopes of GRIN2D

• Correlate protein detection with RNA expression using in situ hybridization

• Consider genetic analysis for GRIN2D variants that might affect epitope recognition

• Employ quantitative image analysis to establish staining thresholds and minimize subjective interpretation

• Use super-resolution microscopy to determine subcellular localization patterns

Control experiments with peptide competition can identify non-specific binding, while multiplexed immunofluorescence can reveal co-expression patterns with other neuronal or endothelial markers to confirm cell-type specific expression.

How can GRIN2D antibodies be integrated into studies of patient-specific variants?

For research on GRIN2D variants related to epileptic encephalopathy:

• Generate variant-specific antibodies for known pathogenic mutations (e.g., Leu670Phe, Ala675Thr)

• Use cell-based assays comparing wild-type and mutant GRIN2D trafficking and expression

• Combine antibody detection with functional calcium imaging to correlate protein expression with channel activity

• Develop screening platforms to test variant response to NMDA receptor antagonists for potential personalized therapies

This integrated approach can guide precision medicine approaches for patients with GRIN2D variants by identifying mutation-specific pharmacological interventions, as demonstrated in cases where memantine was used to target gain-of-function GRIN2D mutations .

What methodological approaches are being used to investigate GRIN2D as a novel tumor endothelial marker?

Research identifying GRIN2D as a tumor endothelial marker in colorectal cancer has employed advanced methodologies:

• Microarray comparison of gene expression between patient-matched colorectal cancer and normal colon samples

• RTqPCR validation of differential expression

• Immunohistochemical characterization of endothelial-specific expression

• siRNA knockdown experiments to assess functional significance in angiogenesis models

• In vivo vaccination approaches using GRIN2D-Fc fusion proteins to target tumor vasculature

These approaches demonstrate GRIN2D's potential as both a biomarker and therapeutic target in colorectal cancer, expanding its relevance beyond neurological disorders.

How can multiplex immunofluorescence with GRIN2D antibodies advance understanding of receptor heterogeneity?

Advanced multiplexing techniques can reveal complex GRIN2D biology:

• Co-staining with other NMDA receptor subunits (GluN1, GluN2A-C) to identify receptor composition

• Combined detection with trafficking markers to assess membrane localization

• Integration with cell-type specific markers to determine expression patterns

• Sequential immunostaining using tyramide signal amplification for highly multiplexed imaging

• Spatial transcriptomics combined with protein detection to correlate transcript and protein levels

These approaches can reveal previously unrecognized heterogeneity in GRIN2D-containing NMDA receptors across different cell types and disease states.

What considerations are important when developing GRIN2D antibodies for therapeutic applications?

For potential therapeutic applications targeting GRIN2D:

• Epitope selection must consider accessibility in the native conformation of the protein

• Humanization of antibodies is essential to reduce immunogenicity

• Antibody format (full IgG, Fab, scFv) affects tissue penetration, particularly for CNS applications

• Fc engineering can modify effector functions based on the desired mechanism of action

• Blood-brain barrier penetrance must be addressed for neurological applications

The successful development of a murine GRIN2D-Fc fusion protein vaccine for colorectal cancer research demonstrates the potential for immunological approaches targeting this receptor .